Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Top Indian Pharma...

    Top Indian Pharma formulators eyeing OTC market: Report

    Written by Ruby Khatun Khatun Published On 2018-04-21T10:30:23+05:30  |  Updated On 21 April 2018 10:30 AM IST
    Top Indian Pharma formulators eyeing OTC market: Report

    Mumbai: Indian pharmaceutical formulators are expected to continue to make investments in consumer healthcare, wellness products, and traditional OTC product categories to grow domestic non-prescription business through organic and inorganic routes, a report said.


    These investments would be driven by the need to further diversify the domestic prescription business, India Ratings and Research (Ind-Ra) said in its report.


    According to Business Monitor International (BMI), India's non-prescription or OTC market contributes around 14.5 percent to the total pharmaceutical sales and is expected to grow to USD 4.2 billion at a CAGR of 8.8 percent over 2017-2022. The growth is likely to be driven by limited household affordability for frequent clinical visits, the convenience of direct purchase and growing preference for self-medication for minor ailments, it said.


    Investments by Indian formulators are likely to be in consumer healthcare and wellness products, apart from the traditional OTC product categories through new launches, brand extensions and switches from prescription products. The non-prescription business includes products in categories such as analgesics, cough, cold and allergy, dermatological, gastrointestinal and lifestyle OTCs such as vitamins, minerals and nutritional supplements and dental products.


    Ind-Ra believes the non-prescription business to contribute a solid 15-20 percent to the domestic revenues of Indian formulators over the next five years.


    Structurally, the margin and return profile of an optimized non-prescription business with a mix of OTC, consumer and wellness products is better than that of an acute prescription portfolio, but may significantly be lower than that for a chronic prescription portfolio.


    The profitability from a non-prescription business happens with a lag, subject to significant investments in media spends and distribution to establish/enhance consumer appeal or brand recall. The agency believes that large Indian formulators with demonstrated brand building capabilities and established distribution network can break-even faster and achieve profitability early.


    While FMCG players are likely to maintain market leadership in consumer products, competition for Indian formulators is expected to be moderate due to inherent strengths and limited product overlap, the report said.


    This strategy is in sharp contrast to some global majors looking for strategic alternatives to exit their mature consumer health business owing to low single-digit growth and shift in focus back to the core prescription business.


    Since the second half of 2017, global majors such as Merck KGaA and Pfizer have announced a potential full or partial sale of their consumer health business as well as strategic partnerships for accelerating deleveraging and to focus on the core prescription business.

    Business Monitor Internationalconsumer healthcareformulatorsIndia Ratings and ResearchIndian pharmaceutical formulatorsinvestInvestmentsMercknon-prescription businessOTC marketPfizerpharmawellness products
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok